Petros Pharmaceuticals's revenue for the
three
months ended in Dec. 2023 was $-0.36 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $5.82 Mil.
Petros Pharmaceuticals's Revenue per Share for the
three
months ended in Dec. 2023 was $-0.15.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.78.
Warning Sign:
Petros Pharmaceuticals Inc revenue per share has been in decline over the past 3 years.
During the past 5 years, Petros Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was -43.50% per year. The lowest was -46.90% per year. And the median was -45.20% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Petros Pharmaceuticals's Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petros Pharmaceuticals's Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's Revenue distribution charts can be found below:
* The bar in red indicates where Petros Pharmaceuticals's Revenue falls into.
Petros Pharmaceuticals Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Petros Pharmaceuticals Revenue Related Terms
Thank you for viewing the detailed overview of Petros Pharmaceuticals's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Petros Pharmaceuticals (Petros Pharmaceuticals) Business Description
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie's disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PTPI has been successfully added to your 